To accelerate the clinical translation of MDH1 as a predictive biomarker, we next interrogated whether MDH1 expression levels modulate drug sensitivity by comparing the IC50 values of standard-of-care antineoplastic agents across lung-cancer cell lines stratified into MDH1-high and MDH1-low cohorts. This evidence concerns the gene MDH1 and lung carcinoma.